Are there any contraindications to BCS and adjuvant radiotherapy in patients with BARD1 mutation?   

BARD1 may be a moderate risk mutation predisposing to breast cancer, but with no contraindications to breast conservation treatment. There may be a slightly increased risk of developing a new primary in the treated breast, much like any other moderate risk gene.